Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials

Acta Psychiatrica Scandinavica

Volumn 131, Issue 3, 2015, Pages 185-196

  Nielsen, R E ^a   Levander, S ^b   Kjaersdam Telleus G ^a   Jensen, S O W ^a   Ostergaard Christensen T ^c   Leucht, S ^d  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b MALMÖ UNIVERSITY   (Sweden)

^c Central Denmark Region   (Denmark)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotics; Cognition; Meta analysis; Schizophrenia

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ARTICLE; COGNITION; CONTROLLED STUDY; EFFECT SIZE; EXECUTIVE FUNCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SKILL; VERBAL MEMORY; WORKING MEMORY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; PSYCHOLOGY; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; COGNITION; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84922670929     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12374     Document Type: Article

References (89)

1. Nielsen RE. Cognition in schizophrenia - a systematic review. Drug Discov Today Ther Strateg 2011;8:43-48.
2. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 2011;37:1209-1217.
3. Szoke A, Trandafir A, Dupont ME, Meary A, Schurhoff F, Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 2008;192:248-257.
4. Dominguez MG, Viechtbauer W, Simons CJ, Van OJ, Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull 2009;135:157-171.
5. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008;165:978-987.
6. Quee PJ, van der Meer L, Krabbendam L et al. Insight change in psychosis: relationship with neurocognition, social cognition, clinical symptoms and phase of illness. Acta Psychiatr Scand 2014;129:126-133.
7. Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr Scand 2014;130:290-299.
8. Kakela J, Panula J, Oinas E, Hirvonen N, Jaaskelainen E, Miettunen J. Family history of psychosis and social, occupational and global outcome in schizophrenia: a meta-analysis. Acta Psychiatr Scand 2014t;130:269-278.
9. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 2010;10:43-57.
10. Nielsen RE, Nielsen J. Antipsychotic drug treatment for patients with schizophrenia. Clin Med Therap 2009;1:1053-1068.
11. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004;161:116-124.
12. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl. 2):S12-S21.
13. Keefe RSE, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64:633-647.
14. Davidson M, Galderisi S, Weiser M et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009;166:675-682.
15. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophr Res 2007;89:211-224.
16. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457-472.
17. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-222.
18. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004;55:1013-1022.
19. Desamericq G, Schurhoff F, Meary A et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol 2014;70:127-134.
20. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962.
21. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-758.
22. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-137.
23. Buchanan RW, Davis M, Goff D et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:5-19.
24. Lezak M, Howieson D, Bigler E, Tranel D. Neuropsychological assessment. 5th edn. New York, NY: Oxford University Press Inc, 2012.
25. Green MF, Nuechterlein KH, Gold JM et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301-307.
26. Duval S, Tweedie R. Trim, and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-463.
27. Abdolahian E, Mohareri F, Bordbar MRF. Haloperidol versus risperidone: a comparison of beneficial effect on cognitive function of patients with chronic schizophrenia. Iran J Psychiatry Behav Sci 2008;2:14-20.
28. Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry 2004;161:364-367.
29. Bender S, Dittmann-Balcar A, Schall U et al. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol 2006;9:135-145.
30. Bilder RM, Goldman RS, Volavka J et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028.
31. Boulay LJ, Labelle A, Bourget D et al. Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: olanzapine versus haloperidol. Cogn Neuropsychiatry 2007;12:322-338.
32. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725.
33. Fagerlund B, Mackeprang T, Gade A, Glenthoj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 2004;9:364-374.
34. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6(Suppl. 2):S13-S20.
35. Goldberg TE, Goldman RS, Burdick KE et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007;64:1115-1122.
36. Green MF, Marshall BD Jr, Wirshing WC et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
37. Green MF, Marder SR, Glynn SM et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002;51:972-978.
38. Grootens KP, Van Veelen NMJ, Sitskoorn MM et al. Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. Eur Neuropsychopharmacol 2010;20:907-912.
39. Gurpegui M, Álvarez E, Bousoño M, Ciudad A, Gómez JC, Olivares JM. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. Eur Neuropsychopharmacol 2007;17:725-734.
40. Harvey PD, Sacchetti E, Galluzzo A et al. A randomized double-blind comparison of ziprasidone vs. Clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr Res 2008;105:138-143.
41. Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double blind, randomized study. Psychopharmacology 2003;169:404-411.
42. Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci 2006;18:54-63.
43. Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 2006;163:1918-1925.
44. Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482.
45. Jerrell JM, Ramirez PM. Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications. Hum Psychopharmacol 2008;23:595-604.
46. Keefe RS, Young CA, Rock SL et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006;81:1-15.
47. Keefe RS, Sweeney JA, Gu H et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1061-1071.
48. Kern RS, Green MF, Cornblatt BA et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 2006;187:312-320.
49. Krakowski MI, Czobor P, Nolan KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol 2008;28:485-493.
50. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine in cognitive function in schizophrenia. J Clin Psychiatry 1994;55:82-87.
51. Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 1999;37:1-11.
52. Lee S, Chou Y, Li M, Wan F, Yen M. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1101-1107.
53. Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 2007;68:368-379.
54. Ljubin T, Milas DZ, Mimica N, Folnegovic-Smalc V, Makaric G. A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. Hum Psychopharmacol 2000;15:513-519.
55. McGurk SR, Carter C, Goldman R et al. The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry 2005;162:1013-1016.
56. Meltzer HY, Bobo WV, Roy A et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274-285.
57. Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:659-665.
58. Mortimer AM, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT. Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Hum Psychopharmacol 2007;22:445-454.
59. Muscatello MRA, Bruno A, Pandolfo G et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011;127:93-99.
60. Nielsen R, Odur F, Østergaard T, Munk-Jørgensen P, Nielsen J. Comparison of the effects of Sertindole and Olanzapine on Cognition: a double-blind randomized 12-week study of patients diagnosed with schizophrenia. Ther Adv Psychopharmacol 2013;4:4-14.
61. Purdon SE, Jones BDW, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249-258.
62. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-149.
63. Remillard S, Pourcher E, Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res 2005;80:99-106.
64. Remillard S, Pourcher E, Cohen H. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia. J Int Neuropsychol Soc 2008;14:110-118.
65. Remillard S, Pourcher E, Cohen H. Long-term skill proceduralization in schizophrenia. J Int Neuropsychol Soc 2010;16:148-156.
66. Riedel M, Müller N, Spellmann I et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007;257:402-412.
67. Riedel M, Spellmann I, Strassnig M et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2007;257:360-370.
68. Rosenheck R, Perlick D, Bingham S et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-2702.
69. Sergi MJ, Green MF, Widmark C et al. Cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry 2007;164:1585-1592.
70. Smith RC, Infante M, Singh A, Khandat A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int J Neuropsychopharmacol 2001;4:239-250.
71. van Veelen NM, Grootens KP, Peuskens J et al. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res 2010;120:191-198.
72. Velligan DI, Newcomer J, Pultz J et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-248.
73. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 2003;64:524-531.
74. Voruganti LP, Awad AG, Parker G et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 2007;96:146-155.
75. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn K. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 2005;30:381-390.
76. Gallhofer B, Jaanson P, Mittoux A, Tanghoj P, Lis S, Krieger S. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007;40:275-286.
77. Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol 2007;30:3-12.
78. Shekhar A, Potter WZ, Lightfoot J et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008;165:1033-1039.
79. Freedman R, Olincy A, Buchanan RW et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165:1040-1047.
80. Pae CU. Role of the cholinesterase inhibitors in the treatment of schizophrenia. Expert Opin Investig Drugs 2013;22:293-298.
81. Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol 2012;26:1167-1174.
82. McGurk SR, Green MF, Wirshing WC et al. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res 2004;68:225-233.
83. Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry 1998;59:184-188.
84. Mork A, Witten LM, Arnt J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology 2009;206:39-49.
85. Burnham KE, Baxter MG, Bainton JR et al. Activation of 5-HT(6) receptors facilitates attentional set shifting. Psychopharmacology 2010;208:13-21.
86. Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 2008;33:2657-2666.
87. Herrera E, Cuetos F, Ribacoba R. Verbal fluency in Parkinson's disease patients on/off dopamine medication. Neuropsychologia 2012;50:3636-3640.
88. Kontis D, Theochari E, Kleisas S et al. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1333-1341.
89. Kawai N, Yamakawa Y, Baba A et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1009-1014.